P.M. BRIEFING : Panel to Look at Generic Drugs
More than 18 months after signs of wrongdoing first surfaced in the generic drug industry, a trade group today formed a panel to look into the scandal that has shaken confidence in such medicines.
The Generic Pharmaceutical Industry Assn. said the experts are being asked to recommend “whatever changes may be necessary to reassure the American people that generic drugs are properly tested and evaluated, and are safe and effective.”
The seven-member panel, which includes former Food and Drug Administration Commissioner Dr. Jere Goyan, will be given a free hand to conduct its investigation and should issue a report by the end of June, the association said.
The industry group plans to pay the experts for their time and expenses.
Since July, 1988, the FDA and the generic drug industry have been confronting a scandal stemming from the bribery convictions of three FDA employees, and the revelations of widespread wrongdoing in the industry.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
